Screener
Zevra Therapeutics, Inc. ZVRA Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockValue.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2026, or December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 250,000,000 shares authorized; 60,917,598 shares issued and 59,341,906 shares outstanding as of June 30, 2026; 58,338,319 shares issued and 56,854,781 shares outstanding as of December 31, 2025 | 6 | 6 |
| Additional paid-in capital | 606,264 | 588,458 |
| Treasury stock, at cost | (10,983) | (10,983) |
| Accumulated deficit | (375,418) | (422,060) |
| Accumulated other comprehensive loss | (2,217) | (764) |
| Total stockholders' equity | 217,652 | 154,657 |
| Total liabilities and stockholders' equity | $302,712 | $284,731 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s treasury stock?
- Zevra Therapeutics, Inc. (ZVRA) reported treasury stock of $10.98M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s treasury stock changed year-over-year?
- Zevra Therapeutics, Inc.'s treasury stock decreased by 0.0% year-over-year, from $10.98M to $10.98M.
- What does treasury stock mean?
- Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.
Ask your AI about Zevra Therapeutics, Inc.'s treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude